Cargando…
Advances in clinical chemistry. Volume 71 /
This volume the latest installment in this internationally acclaimed series. It contains chapters authored by world-renowned clinical laboratory scientists, physicians, and research scientists. The serial discusses the latest and most up-to-date technologies related to the field of clinical chemistr...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Academic Press,
2015.
|
| Colección: | Advances in Clinical Chemistry.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn923738621 | ||
| 003 | OCoLC | ||
| 005 | 20231120112027.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 151012s2015 ne ob 001 0 eng d | ||
| 040 | |a OPELS |b eng |e rda |e pn |c OPELS |d OCLCQ |d N$T |d CDX |d YDXCP |d EBLCP |d UKNRU |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO | ||
| 066 | |c (S | ||
| 019 | |a 925438620 |a 928483679 |a 931586127 |a 932328963 |a 1086233922 |a 1089983324 | ||
| 020 | |a 9780128025222 |q (electronic bk.) | ||
| 020 | |a 0128025220 |q (electronic bk.) | ||
| 020 | |z 9780128022566 | ||
| 020 | |a 0128022566 | ||
| 020 | |a 9780128022566 | ||
| 035 | |a (OCoLC)923738621 |z (OCoLC)925438620 |z (OCoLC)928483679 |z (OCoLC)931586127 |z (OCoLC)932328963 |z (OCoLC)1086233922 |z (OCoLC)1089983324 | ||
| 050 | 4 | |a RB40 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.0756 |2 23 |
| 245 | 0 | 0 | |a Advances in clinical chemistry. |n Volume 71 / |c Gregory Makowski, editor. |
| 264 | 1 | |a Amsterdam : |b Academic Press, |c 2015. | |
| 300 | |a 1 online resource (332 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Advances in Clinical Chemistry ; |v v. Volume 71 | |
| 504 | |a Includes bibliographical references and index. | ||
| 500 | |a Title from title details screen (ScienceDirect, viewed October 12, 2015). | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Title page; Table of Contents; Copyright; Contributors; Preface; Chapter One: Biomarkers in Breast Cancer: Where Are We and Where Are We Going?; Abstract; 1 Use of Biomarkers in the Identification of Women at Increased Risk of Developing Breast Cancer (Risk Assessment); 2 Use of Biomarkers in Determining Prognosis; 3 Use of Biomarkers in Guiding Treatment; 4 Use of Biomarkers in the Postoperative Follow-Up of Asymptomatic Patients Following Curative Surgery; 5 Use of Biomarkers in Monitoring Therapy in Patients with Metastasis; 6 Emerging Biomarkers for Breast Cancer; 7 Conclusion | |
| 505 | 8 | |a AcknowledgmentsChapter Two: Polycystic Ovary Syndrome-Epigenetic Mechanisms and Aberrant MicroRNA; Abstract; 1 Introduction; 2 The Epigenetic Landscape; 3 miRNA; 4 Conclusions; Acknowledgments; Chapter Three: EN2 in Prostate Cancer; Abstract; 1 Introduction; 2 Risk Factors and Conventional Biomarkers of Prostate Cancer; 3 Biomarkers with Clinical Application in Urine; 4 Antitumor Antibodies as Biomarkers; 5 The Homeobox Gene Superfamily; 6 The Biology of En; 7 En in Cancer; 8 En as a Potential Biomarker in Cancer; 9 EN2 in Prostate Cancer | |
| 505 | 8 | |a 10 EN2 as a Diagnostic Marker and Marker of Significant Disease11 EN2 in Men at High Risk of Prostate Cancer; 12 Future Perspectives; 13 Conclusion; Chapter Four: Cytochrome P450 in Cancer Susceptibility and Treatment; Abstract; 1 Introduction; 2 Classification, Nomenclature, and Structure of Cytochromes P450; 3 Drug Metabolism; 4 Genetic Variations in CYP450 Isoforms; 5 CYP450 in Cancer Susceptibility; 6 CYP450 in Anticancer Therapy; 7 Conclusion; Acknowledgments; Chapter Five: The Importance of Accurately Assessing Renal Function in the Neonate and Infant; Abstract; 1 Introduction | |
| 505 | 8 | |a 2 The Normal Development of Renal Function Before Birth3 Adaptation of Hemodynamics and Renal Function After Birth; 4 Can Nephrogenesis Continue After Preterm Birth?; 5 Measuring Renal Function; 6 Neonatal Kidney Size and Renal Function in Preterm Infants; 7 Should We Move to CysC-Derived eGFR When Dosing Aminoglycosides and Other Renally Excreted in Neonates?; Acknowledgments; Chapter Six: Systematic Assessment of the Hemolysis Index: Pros and Cons; Abstract; 1 Introduction; 2 The Hemolysis Index; 3 Pros and Cons; 4 Conclusions | |
| 520 | 8 | |a This volume the latest installment in this internationally acclaimed series. It contains chapters authored by world-renowned clinical laboratory scientists, physicians, and research scientists. The serial discusses the latest and most up-to-date technologies related to the field of clinical chemistry and is the benchmark for novel analytical approaches in the clinical laboratory. | |
| 650 | 0 | |a Clinical chemistry. | |
| 650 | 2 | |a Chemistry, Clinical |0 (DNLM)D002624 | |
| 650 | 6 | |a Chimie clinique. |0 (CaQQLa)201-0016714 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Clinical chemistry |2 fast |0 (OCoLC)fst00864330 | |
| 700 | 1 | |a Makowski, Gregory S. |q (Gregory Stephen), |e editor. | |
| 776 | 0 | 8 | |i Print version: |a Makowski, Gregory S. |t Advances in Clinical Chemistry. |d : Elsevier Science, �2015 |
| 830 | 0 | |a Advances in Clinical Chemistry. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128022566 |z Texto completo |
| 880 | 8 | |6 505-00/(S |a Chapter Seven: Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and AtherosclerosisAbstract; 1 Introduction; 2 PPARα Expression; 3 PPARα Structure and Activation; 4 PPARα and Lipid Metabolism; 5 PPARα and Lipoprotein Metabolism; 6 The Roles of PPARα in Atherosclerosis; 7 Therapeutic Potential of PPARα Agonists in Atherosclerosis and Dyslipidemia; 8 Conclusions and Perspectives; Acknowledgments; Index | |